DT&CRO (A383930) Stock Overview
Operates as a full-service CRO provider in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
A383930 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
DT&CRO CO., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩2,760.00 |
| 52 Week High | ₩9,370.00 |
| 52 Week Low | ₩2,250.00 |
| Beta | 2.27 |
| 1 Month Change | 16.46% |
| 3 Month Change | -8.00% |
| 1 Year Change | -61.98% |
| 3 Year Change | -50.80% |
| 5 Year Change | n/a |
| Change since IPO | -60.14% |
Recent News & Updates
Benign Growth For DT&CRO CO., Ltd. (KOSDAQ:383930) Underpins Stock's 25% Plummet
Dec 30
Why Investors Shouldn't Be Surprised By DT&CRO CO., Ltd.'s (KOSDAQ:383930) Low P/S
Nov 15Shareholder Returns
| A383930 | KR Life Sciences | KR Market | |
|---|---|---|---|
| 7D | 4.7% | 2.5% | 7.6% |
| 1Y | -62.0% | 2.8% | 103.7% |
Return vs Industry: A383930 underperformed the KR Life Sciences industry which returned 2.8% over the past year.
Return vs Market: A383930 underperformed the KR Market which returned 103.7% over the past year.
Price Volatility
| A383930 volatility | |
|---|---|
| A383930 Average Weekly Movement | 9.5% |
| Life Sciences Industry Average Movement | 8.6% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in KR Market | 13.1% |
| 10% least volatile stocks in KR Market | 2.9% |
Stable Share Price: A383930 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A383930's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | n/a | www.dtncro.com |
DT&CRO CO., Ltd. operates as a full-service CRO provider in South Korea. The company conducts a series of consigned studies ranging from non-clinical GLP toxicity, PK, and efficacy tests required for licensing of pharmaceuticals, chemicals, health functional foods, cosmetics, and medical devices to analysis, bioactivity, clinical trials, and licensing consulting. DT&CRO CO., Ltd.
DT&CRO CO., Ltd. Fundamentals Summary
| A383930 fundamental statistics | |
|---|---|
| Market cap | ₩35.28b |
| Earnings (TTM) | ₩4.17b |
| Revenue (TTM) | ₩44.36b |
Is A383930 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A383930 income statement (TTM) | |
|---|---|
| Revenue | ₩44.36b |
| Cost of Revenue | ₩43.49b |
| Gross Profit | ₩868.69m |
| Other Expenses | -₩3.30b |
| Earnings | ₩4.17b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 326.46 |
| Gross Margin | 1.96% |
| Net Profit Margin | 9.41% |
| Debt/Equity Ratio | 137.6% |
How did A383930 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/14 05:43 |
| End of Day Share Price | 2026/02/13 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
DT&CRO CO., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.